Operating Lease, Right-of-Use Asset of Jazz Pharmaceuticals plc from 31 Dec 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Jazz Pharmaceuticals plc quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2018 to 30 Sep 2025.
  • Jazz Pharmaceuticals plc Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $61,204,000, a 21% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Jazz Pharmaceuticals plc Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $61,204,000 -$15,960,000 -21% 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $63,082,000 -$10,063,000 -14% 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $49,181,000 -$12,456,000 -20% 31 Mar 2025 10-Q 07 May 2025 2025 Q1
Q4 2024 $53,582,000 -$11,758,000 -18% 31 Dec 2024 10-Q 05 Nov 2025 2025 Q3
Q3 2024 $77,164,000 +$12,126,000 +19% 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $73,145,000 +$4,105,000 +5.9% 30 Jun 2024 10-Q 01 Aug 2024 2024 Q2
Q1 2024 $61,637,000 -$13,901,000 -18% 31 Mar 2024 10-Q 02 May 2024 2024 Q1
Q4 2023 $65,340,000 -$7,986,000 -11% 31 Dec 2023 10-K 26 Feb 2025 2024 FY
Q3 2023 $65,038,000 -$8,690,000 -12% 30 Sep 2023 10-Q 08 Nov 2023 2023 Q3
Q2 2023 $69,040,000 -$9,325,000 -12% 30 Jun 2023 10-Q 09 Aug 2023 2023 Q2
Q1 2023 $75,538,000 -$7,874,000 -9.4% 31 Mar 2023 10-Q 10 May 2023 2023 Q1
Q4 2022 $73,326,000 -$13,260,000 -15% 31 Dec 2022 10-K 28 Feb 2024 2023 FY
Q3 2022 $73,728,000 -$15,900,000 -18% 30 Sep 2022 10-Q 09 Nov 2022 2022 Q3
Q2 2022 $78,365,000 -$70,889,000 -47% 30 Jun 2022 10-Q 03 Aug 2022 2022 Q2
Q1 2022 $83,412,000 -$42,326,000 -34% 31 Mar 2022 10-Q 04 May 2022 2022 Q1
Q4 2021 $86,586,000 -$42,583,000 -33% 31 Dec 2021 10-K 01 Mar 2023 2022 FY
Q3 2021 $89,628,000 -$41,089,000 -31% 30 Sep 2021 10-Q 09 Nov 2021 2021 Q3
Q2 2021 $149,254,000 +$16,075,000 +12% 30 Jun 2021 10-Q 03 Aug 2021 2021 Q2
Q1 2021 $125,738,000 -$10,238,000 -7.5% 31 Mar 2021 10-Q 04 May 2021 2021 Q1
Q4 2020 $129,169,000 -$10,216,000 -7.3% 31 Dec 2020 10-K 01 Mar 2022 2021 FY
Q3 2020 $130,717,000 -$11,161,000 -7.9% 30 Sep 2020 10-Q 02 Nov 2020 2020 Q3
Q2 2020 $133,179,000 -$11,567,000 -8% 30 Jun 2020 10-Q 04 Aug 2020 2020 Q2
Q1 2020 $135,976,000 -$11,389,000 -7.7% 31 Mar 2020 10-Q 05 May 2020 2020 Q1
Q4 2019 $139,385,000 +$139,385,000 31 Dec 2019 10-K 23 Feb 2021 2020 FY
Q3 2019 $141,878,000 30 Sep 2019 10-Q 05 Nov 2019 2019 Q3
Q2 2019 $144,746,000 30 Jun 2019 10-Q 06 Aug 2019 2019 Q2
Q1 2019 $147,365,000 31 Mar 2019 10-Q 07 May 2019 2019 Q1
Q4 2018 $0 31 Dec 2018 10-Q 05 Nov 2019 2019 Q3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.